Liling Wan

Liling Wan

Auto-generated profile, based on publicly available information

Liling Wan

Department of Cancer Biology, University of Pennsylvania Perelman School of Medicine, Philadelphia, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2019 in Nature
Verified
Journal Article
Closed access
PDF file
LWLiling Wan
Liling Wan
SCShasha Chong
Shasha Chong
Fan XuanFan Xuan
Fan Xuan
ALAngela Liang
Angela Liang
XCXiaodong Cui
Xiaodong Cui
CAC. David Allis
C. David Allis

1 December 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
XWXue Qing David. Wang
Xue Qing David. Wang
DFDandan Fan
Dandan Fan
QHQinyu Han
Qinyu Han
YLYiman Liu
Yiman Liu
HMHongzhi Miao
Hongzhi Miao
XZXiaotian Zhang
Xiaotian Zhang
Nucleophosmin (NPM1) is a ubiquitously expressed nucleolar protein with a wide range of biological functions. In 30% of acute myeloid leukemia (AML), the terminal exon of NPM1 is often found mutated, resulting in the addition of a nuclear export signal and a shift of the protein to the cytoplasm (NPM1c). AMLs carrying this mutation have aberrant expression of the HOXA/B genes, whose overexpression leads to leukemogenic transformation. Here, for the first time, we comprehensively prove that NPM1c binds to a subset of active gene promoters in NPM1c AMLs, including well-known leukemia-driving genes—HOXA/B cluster genes and MEIS1. NPM1c sustains the active transcription of key target genes by orchestrating a transcription hub and maintains the active chromatin landscape by inhibiting the activity of histone deacetylases. Together, these findings reveal the neomorphic function of NPM1c as a transcriptional amplifier for leukemic gene expression and open up new paradigms for therapeutic intervention. Significance: NPM1 mutation is the most common mutation in AML, yet the mechanism of how the mutant protein results in AML remains unclear. Here, for the first time, we prove mutant NPM1 directly binds to active chromatin regions and hijacks the transcription of AML-driving genes. See related article by Uckelmann et al., p. 746. This article is highlighted in the In This Issue feature, p. 517

21 October 2022 in Molecular Cell
Verified
Journal Article
Closed access
LSLele Song
Lele Song
XYXinyi Yao
Xinyi Yao
HLHangpeng Li
Hangpeng Li
BPBo Peng
Bo Peng
ABAlan P. Boka
Alan P. Boka
LWLiling Wan
Liling Wan

2 September 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
YLYiman Liu
Yiman Liu
QLQinglan Li
Qinglan Li
FAFatemeh Alikarami
Fatemeh Alikarami
DBDeclan R. Barrett
Declan R. Barrett
LMLeila Mahdavi
Leila Mahdavi
LWLiling Wan
Liling Wan
The chromatin reader eleven–nineteen leukemia (ENL) has been identified as a critical dependency in acute myeloid leukemia (AML), but its therapeutic potential remains unclear. We describe a potent and orally bioavailable small-molecule inhibitor of ENL, TDI-11055, which displaces ENL from chromatin by blocking its YEATS domain interaction with acylated histones. Cell lines and primary patient samples carrying MLL rearrangements or NPM1 mutations are responsive to TDI-11055. A CRISPR-Cas9–mediated mutagenesis screen uncovers an ENL mutation that confers resistance to TDI-11055, validating the compound's on-target activity. TDI-11055 treatment rapidly decreases chromatin occupancy of ENL-associated complexes and impairs transcription elongation, leading to suppression of key oncogenic gene expression programs and induction of differentiation. In vivo treatment with TDI-11055 blocks disease progression in cell line– and patient-derived xenograft models of MLL-rearranged and NPM1-mutated AML. Our results establish ENL displacement from chromatin as a promising epigenetic therapy for molecularly defined AML subsets and support the clinical translation of this approach. Significance: AML is a poor-prognosis disease for which new therapeutic approaches are desperately needed. We developed an orally bioavailable inhibitor of ENL, demonstrated its potent efficacy in MLL-rearranged and NPM1-mutated AML, and determined its mechanisms of action. These biological and chemical insights will facilitate both basic research and clinical translation. This article is highlighted in the In This Issue feature, p. 2483

23 April 2024 in Cancer Discovery
Verified
Journal Article
Open access
YLYiman Liu
Yiman Liu
QLQinglan Li
Qinglan Li
LSLele Song
Lele Song
CGChujie Gong
Chujie Gong
STSylvia Tang
Sylvia Tang
LWLiling Wan
Liling Wan
Gain-of-function mutations in the histone acetylation “reader” eleven-nineteen-leukemia (ENL), found in acute myeloid leukemia (AML) and Wilms tumor, are known to drive condensate formation and gene activation in cellular systems. However, their role in tumorigenesis remains unclear. Using a conditional knock-in mouse model, we show that mutant ENL perturbs normal hematopoiesis, induces aberrant expansion of myeloid progenitors, and triggers rapid onset of aggressive AML. Mutant ENL alters developmental and inflammatory gene programs in part by remodeling histone modifications. Mutant ENL forms condensates in hematopoietic stem/progenitor cells at key leukemogenic genes, and disrupting condensate formation via mutagenesis impairs its chromatin and oncogenic function. Moreover, treatment with an acetyl-binding inhibitor of the mutant ENL displaces these condensates from target loci, inhibits mutant ENL-induced chromatin changes, and delays AML initiation and progression in vivo. Our study elucidates the function of ENL mutations in chromatin regulation and tumorigenesis and demonstrates the potential of targeting pathogenic condensates in cancer treatment. Significance: A direct link between ENL mutations, condensate formation, and tumorigenesis is lacking. This study elucidates the function and mechanism of ENL mutations in leukemogenesis, establishing these mutations as bona fide oncogenic drivers. Our results also support the role of condensate dysregulation in cancer and reveal strategies to target pathogenic condensates.

23 May 2024 in Current Opinion in Genetics & Development
Verified
Journal Article
Closed access
KMKaeli M Mathias
Kaeli M Mathias
YLYiman Liu
Yiman Liu
LWLiling Wan
Liling Wan